Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02363335 · ClinicalTrials.gov registry record · Phase 1
The Role of Phosphodiesterase Inhibitors in Incretin Secretion
A Phase 1 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02363335: Completed Phase 1 study, sponsored by National Institute on Aging (NIA).
NCT02363335 is a Phase 1 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02363335, a Phase 1 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
Background: The drug Roflumilast (Daliresp) is used to treat Chronic Obstructive Pulmonary Disease (COPD). COPD is a lung disease that makes it difficult to breathe. Studies have shown that this drug decreased the blood sugar of people with type 2 diabetes. Sitagliptin (Januvia) is a medication presently used to treat diabetes. Researchers think that both of these drugs may decrease blood sugar by causing an increase in the hormone GLP-1.This hormone is secreted in the small intestines and stomach and is also known as an incretin. Researchers want to study how these drugs affect blood sugar, insulin, and other hormones in the blood. Objectives: * To study the effects of Roflumilast (Daliresp) and Sitagliptin (Januvia) on blood sugar and insulin. * To better understand GLP-1 and other gut hormones. This may lead to new treatments for type 2 diabetes. Eligibility: * Healthy volunteers age 21 55. * Body Mass Index (BMI) less than 30 Design: -This study will require one screening visit and four study visits, scheduled about 3-weeks apart. Screening visit requires participants to arrive after fasting for 10 hours and have the following: * Medical history, physical exam, height, weight, blood pressure measurements and blood and urine tests. * A 2-hour oral glucose tolerance test (OGTT). Participants will drink an orange-flavored drink containing 75 grams of sugar (300 calories). A blood sample will be taken prior to drinking the beverage and 2-hours later. * An electrocardiogram (EKG) to measure the electrical activity of the heart. * Questionnaires about risk for depression or suicide. Study visits 1to 4: * Participants will arrive the evening prior and blood work will be done to confirm eligibility. They will not eat or drink anything except water starting at 8:00 p.m. * About 6:30 a.m. the following day, an I.V. (small plastic tube) will be placed in an arm vein and used to take 20 blood samples over a period of about 11 hours. * Participants will receive on
Primary Outcome
GIP \& GLP-1 response to a mixed meal.
Interventions
- OTHER Placebo
- OTHER Roflumilast/Sitagliptin
- OTHER Sitagliptin
- OTHER Roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-02-13 |
| Est. Completion | 2016-09-19 |
| Phase | Phase 1 |
What the finished NCT02363335 record still lists
NCT02363335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02363335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02363335 about?
NCT02363335 is a clinical study titled "The Role of Phosphodiesterase Inhibitors in Incretin Secretion". Background: The drug Roflumilast (Daliresp) is used to treat Chronic Obstructive Pulmonary Disease (COPD). COPD is a lung disease that makes it difficult to breathe. Studies have shown that this drug decreased the blood sugar of people with type 2 diabetes. Sitagliptin (Januvia) is a medication pre...
What is the current status of trial NCT02363335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2015-02-13. Estimated completion is 2016-09-19.
What interventions are being tested in trial NCT02363335?
The interventions under investigation include: Placebo (OTHER), Roflumilast/Sitagliptin (OTHER), Sitagliptin (OTHER), Roflumilast (OTHER).
Who is sponsoring clinical trial NCT02363335?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02363335's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI